Literature DB >> 6388253

A comparison of 100 mg atenolol and 100 mg metoprolol once a day at rest and during exercise in hypertensives.

O R Nilsson, J H Atterhög, J Castenfors, L Jorfelt, B E Karlberg, T Thulin, K Tolagen, S Wettre, K P Ohman.   

Abstract

The effects of once daily dosage of the two cardioselective beta-adrenoceptor blocking agents, atenolol and metoprolol, were studied in 26 patients with primary hypertension. The study was a randomized double-blind cross-over trial with placebo run-in and wash-out. Assessment of effect was performed about 1 and 25 hours after dosing. At rest, both atenolol and metoprolol lowered the blood pressure (BP) and heart rate (HR) compared to placebo. Atenolol induced a more effective BP reduction than metoprolol, especially 25 hours after drug intake. During exercise 1 hour after dosing both drugs reduced BP and HR to a similar extent, whereas 25 hours after dosing atenolol gave a more efficient BP and HR reduction than metoprolol. Our data show that both 100 mg atenolol and 100 mg metoprolol are effective antihypertensive beta-blockers at rest and during exercise, 1 hour after intake. Metoprolol was less effective than atenolol 25 hours after dosing probably due to its shorter plasma half-life, thus implying a twice daily regimen for metoprolol in standard preparation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6388253     DOI: 10.1111/j.0954-6820.1984.tb03808.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  3 in total

Review 1.  Beta-adrenoceptor blockade and exercise. An update.

Authors:  M A Van Baak
Journal:  Sports Med       Date:  1988-04       Impact factor: 11.136

2.  Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study.

Authors:  Donald Redelmeier; Damon Scales; Alexander Kopp
Journal:  BMJ       Date:  2005-10-06

Review 3.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.